Dexmedetomidine Exerts an Anti-inflammatory Effect via α2 Adrenoceptors to Prevent Lipopolysaccharide-induced Cognitive Decline in Mice

Abstract

Background Clinical studies have shown that dexmedetomidine ameliorates cognitive decline in both the postoperative and critical care settings. This study determined the mechanism(s) for the benefit provided by dexmedetomidine in a medical illness in mice induced by lipopolysaccharide. Methods Cognitive decline, peripheral and hippocampal inflammation, blood–brain barrier permeability, and inflammation resolution were assessed in male mice. Dexmedetomidine was administered in the presence of lipopolysaccharide and in combination with blockers. Cultured macrophages (RAW 264.7; BV-2) were exposed to lipopolysaccharide ± dexmedetomidine ± yohimbine; tumor necrosis factor α release into the medium and monocyte NFκB activity was determined. Results In vivo, lipopolysaccharide-induced cognitive decline and inflammation (mean ± SD) were reversed by dexmedetomidine (freezing time, 55.68 ± 12.31 vs. 35.40 ± 17.66%, P = 0.0286, n = 14; plasma interleukin [IL]-1β: 30.53 ± 9.53 vs. 75.68 ± 11.04 pg/ml, P < 0.0001; hippocampal IL-1β: 3.66 ± 1.88 vs. 28.73 ± 5.20 pg/mg, P < 0.0001; n = 8), which was prevented by α2 adrenoceptor antagonists. Similar results were found in 12-month-old mice. Lipopolysaccharide also increased blood–brain barrier leakage, inflammation-resolution orchestrator, and proresolving and proinflammatory mediators; each lipopolysaccharide effect was attenuated by dexmedetomidine, and yohimbine prevented dexmedetomidine’s attenuating effect. In vitro, lipopolysaccharide-induced tumor necrosis factor α release (RAW 264.7: 6,308.00 ± 213.60 vs. 7,767.00 ± 358.10 pg/ml, P < 0.0001; BV-2: 1,075.00 ± 40.41 vs. 1,280.00 ± 100.30 pg/ml, P = 0.0003) and NFκB–p65 activity (nuclear translocation [RAW 264.7: 1.23 ± 0.31 vs. 2.36 ± 0.23, P = 0.0031; BV-2: 1.08 ± 0.26 vs. 1.78 ± 0.14, P = 0.0116]; phosphorylation [RAW 264.7: 1.22 ± 0.40 vs. 1.94 ± 0.23, P = 0.0493; BV-2: 1.04 ± 0.36 vs. 2.04 ± 0.17, P = 0.0025]) were reversed by dexmedetomidine, which was prevented by yohimbine. Conclusions Preclinical studies suggest that the cognitive benefit provided by dexmedetomidine in mice administered lipopolysaccharide is mediated through α2 adrenoceptor–mediated anti-inflammatory pathways. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New

A Noradrenergic Lesion Attenuates Surgery-Induced Cognitive Impairment in Rats by Suppressing Neuroinflammation

“… Zhang et al (2018) found that sustained stimulation of β 2 and β 3 receptors increased the levels of TNF-α, IL-6, and IL-1β in the plasma and CSF, while microglia and astrocytes in the spinal cord were activated. A recent study suggested that α 2 -AR also participates in regulating neuroinflammation, and dexmedetomidine treatment prevents LPS-induced cognitive decline and neuroinflammation by inhibiting nuclear factor kappa B (NF-κB) through a pathway mediated by α 2 -AR ( Li et al, 2020 ). However, the specific pathophysiological mechanism by which LCNE regulates neuroinflammation is still unclear.…”

Effect of different administration and dosage of dexmedetomidine in the reduction of emergence agitation in children: a meta-analysis of randomized controlled trials with sequential trial analysis

“…Second, DEX has proven to have opioid-sparing properties, and pain is one of the most important risk factors for EA in children (1). Third, recent studies revealed that DEX might have antiinflammatory, organ-protective, and neuroprotective effects, which may play a key role in preventing EA (1,87,88).…”

Dexmedetomidine Alleviates Microglia-Induced Spinal Inflammation and Hyperalgesia in Neonatal Rats by Systemic Lipopolysaccharide Exposure

“…As DEX displays an anti-inflammatory and neuroprotective property ( Li R. et al, 2020 ), we, thus, investigated whether DEX plays a role in the protection of neonatal rats from anti-inflammation and its possible mechanism. We found that consistent with the previous result, the rats in the Saline + LPS group showed significantly increased levels of IL-1β and TNF-α in the serum compared with the rats in the saline + saline group (IL-1β: 6,316.41 ± 896.03 vs. 38.81 ± 11.87, P < 0.01; TNF-α: 1,702.62 ± 118.48 vs. 36.53 ± 11.94, P < 0.001).…”